“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,” said Mr. Azelby. “I look forward to working with Terns’ ...
A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
The global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x ...
Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
A doctor emphasized that ozempic, a lab-engineered drug, effectively activates GLP-1 receptors for weight loss, unlike foods ...
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback